Founding Chief Executive Officer and
Director Olav Bergheim to Depart
Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company” or
“Adagio”), a leading innovator in catheter ablation technologies
for treatment of cardiac arrhythmias, today announced that founder
Olav Bergheim departed as Chief Executive Officer (“CEO”) and
Chairperson of the Board of Directors of the Company, effective
December 13, 2024. Concurrently, the Company announced the
appointment of Todd Usen, as Chief Executive Officer and Director
of the Company and Orly Mishan, as Chairperson of the Board of
Directors, effective December 13, 2024. Mr. Bergheim will serve as
an advisor to the Company and will support Mr. Usen with the
transition through December 13, 2025.
“We are grateful to Olav for his dedication and contributions to
Adagio. Under his leadership the Company made substantial clinical
and operational strides, and is NASDAQ-listed,” said Orly Mishan.
“We are extremely fortunate to add Todd, who has a breadth of
commercial and operational experience and a proven track record
leading large and complex medical device businesses, to the Adagio
team. Todd has demonstrated exceptional leadership in building,
restructuring, and growing public and private organizations. His
efforts have been driven by a strong focus on corporate
development, product innovation, logistics and go-to-market
strategies.”
Before joining Adagio, Todd served as President & CEO of
Minerva Surgical, where he successfully restructured the
organization, completed successful financings, and drove
significant top-line growth. Prior to that, he was CEO of Activ
Surgical, overseeing FDA/CE clearance of advanced surgical imaging
technology and leading four fundraising rounds totaling over $92
million. Earlier, Todd led a $2B+ business as President, Medical
Systems Group at Olympus Corporation, where he drove strategic
expansion, operational restructuring, and successful M&A
activities. His career also includes executive roles at Smith and
Nephew and Boston Scientific Corporation. Todd currently serves as
Executive Chairman of medical robotics company Rob Surgical,
Chairman of NeoPredics, and Director of Alesi Surgical.
“I’m thrilled to join Adagio at this important junction in the
Company’s history, supporting initial commercial efforts in Europe,
and the FULCRUM-VT trial enrollment in the United States,” said
Todd Usen. “With a growing body of evidence demonstrating both the
safety and effectiveness of Adagio’s Ultra-Low Temperature
Cryoablation technology, and marked enthusiasm of users in both
Europe and North America, I believe that Adagio’s VT Cryoablation
System with vCLAS™ catheter will become the future standard of care
for treatment of patients with ventricular tachycardia.”
“It has been an honor to lead Adagio over the last 13 years
delivering on our mission of improving the quality of life and
long-term outcomes in patients with cardiac arrhythmias. I am proud
of what we have accomplished together, and I am confident that
Adagio is poised for continued success,” said Olav Bergheim.
About Adagio Medical Holdings, Inc.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) is an early
commercial stage medical device company located in Laguna Hills,
California focusing on developing innovative cryoablation
technologies that create contiguous, transmural lesions to treat
cardiac arrhythmias, including paroxysmal and persistent atrial
fibrillation, atrial flutter, and ventricular tachycardia.
FULCRUM-VT (Feasibility of Ultra-Low
Temperature Cryoablation in Recurring
Monomorphic Ventricular Tachycardia,
NCT05675865) is a prospective, multi-center, open-label, single-arm
study, enrolling 206 patients with structural heart disease of both
ischemic and non-ischemic cardiomyopathy, indicated for catheter
ablation of drug refractory ventricular tachycardia (VT) in
accordance with current treatment guidelines. The results of the
study will be used to obtain FDA premarket approval (PMA) for
Adagio’s VT Cryoablation System with the vCLAS™ cryoablation
catheter with industry broadest indication for purely endocardial
ablation of scar-mediated VT.
Forward-Looking Statements
Certain statements in this press release (this “Press Release”)
may be considered “forward-looking statements” within the meaning
of the “safe harbor” provisions of the United States Private
Securities Litigation Reform Act of 1995. Forward-looking
statements generally relate to future events or future financial or
operating performance of the Company. For example, any statements
that refer to expectations, projections or other characterizations
of future events or circumstances are forward-looking statements.
In some cases, you can identify forward-looking statements by
terminology such as “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “forecast,” “future,” “intend,” “may,”
“might,” “plan,” “possible,” “potential,” “predict,” “project,”
“propose,” “seek,” “should,” “strive,” “will,” or “would” or the
negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks,
uncertainties, and other factors which may be beyond the control of
the Company and could cause actual results to differ materially
from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and
assumptions that, while considered reasonable by the Company and
its management, are inherently uncertain. The Company cautions you
that these statements are based on a combination of facts and
factors currently known and projections of the future, which are
inherently uncertain. There are risks and uncertainties described
in the definitive proxy/final prospectus relating to the Business
Combination, which was filed by the Company with the U.S.
Securities and Exchange Commission (the “SEC”), and described in
other documents filed by the Company from time to time with the
SEC. These filings may identify and address other important risks
and uncertainties that could cause actual events and results to
differ materially from those contained in the forward-looking
statements. The Company cannot assure you that the forward-looking
statements in this communication will prove to be accurate.
Nothing in this Press Release should be regarded as a
representation or warranty by any person that the forward-looking
statements set forth herein will be achieved or that any of the
contemplated results of such forward-looking statements will be
achieved, in any specified time frame, or at all. You should not
place undue reliance on forward-looking statements, which speak
only as of the date they are made in this Press Release. Subsequent
events and developments may cause those views to change. The
Company does not undertake any duty to update these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241216084700/en/
Media Contact Ilya Grigorov Vice President, Global
Marketing and Product Management of Adagio Medical, Inc.
igrigorov@adagiomedical.com
Investor Contact IR@adagiomedical.com
Adagio Medical (NASDAQ:ADGM)
過去 株価チャート
から 11 2024 まで 12 2024
Adagio Medical (NASDAQ:ADGM)
過去 株価チャート
から 12 2023 まで 12 2024
